Other Content - BioPharm International

ADVERTISEMENT

Other Content

Legislation to Protect Subjects in Clinical Trials Introduced

May 16, 2013

Legislation designed to protect clinical trial study participants, close loopholes, and bring certainty and public transparency to research studies, has been introduced.

Report Previews Future of U.S. Biosimilar Market

May 15, 2013

Thomson Reuters released a report that provides a view of the challenges facing companies entering the United States biosimilar drug market.

Amgen Forms New Joint Venture to Commercialize Vectibix in China

May 13, 2013

Amgen and Zhejiang Beta Pharma have signed an agreement to form a joint venture to commercialize Amgen's Vectibix (panitumumab) in the Chinese market. The aim is to quickly and efficiently deliver Vectibix to patients in China. Vectibix is a fully human anti-epidermal growth factor receptor (EGFR) antibody approved by FDA for the treatment of metastatic colorectal cancer.

Tamiflu Leads Q1 Drug Sales Growth

May 7, 2013

In the first quarter of 2013, the rankings for the top five drugs by sales shifted a bit, but exhibited positive growth for the quarter.

Rigaku Raman - Handheld 1064 nm Raman for Pharmaceutical Excipients Identification

April 29, 2013

Rigaku Raman - Handheld 1064 nm Raman for Pharmaceutical Excipients Identification

Parker Hannifin - HarvestClearTM Filtration System for harvest of small-scale bioreactors

April 29, 2013

Parker Hannifin - HarvestClearTM Filtration System for harvest of small-scale bioreactors

Astellas and Ambrx Collaborate on Antibody Drug Conjugates for Oncology

April 8, 2013

Astellas and Ambrx have entered into a collaboration to discover and develop novel antibody drug conjugates (ADCs) for an undisclosed number of targets in oncology. ADCs enable targeted delivery of drugs to the target tissue.

Fluid Imaging BP - Automatically Detect, Differentiate Agglomerated Proteins

March 13, 2013

Fluid Imaging BP - Automatically Detect, Differentiate Agglomerated Proteins

Roche Chairman to Step Down in 2014

March 5, 2013

Franz B. Humer, chairman of the board of directors of the Roche Group, will not stand for re-election to the Board in 2014.

ADVERTISEMENT

ADVERTISEMENT

Click here